Status:
RECRUITING
Predictive Value of Soluble CD146 in Glioblastoma Patients
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in re...
Eligibility Criteria
Inclusion
- \- Adult patients with recurrent IDHwt glioblastoma
- Relapse after standard first line treatment (radio-chemotherapy)
- Candidate for bevacizumab treatment
- Able to be monitored by MRI
- KPS ≥ 60%
- Written signed consent form
Exclusion
- Pregnancy or breast feeding
- Life expectancy less than 3 months
- Bevacizumab in first line treatment
- Other concomitant life-threatening disease
- Under legal protection
Key Trial Info
Start Date :
January 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06001281
Start Date
January 30 2024
End Date
December 1 2026
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Neuro-oncologie
Marseille, France, 13005